A Phase 1 study to evaluate IK-930 in subjects with advanced solid tumors

计划入组 31 人 · 首次发布于 2024 年 5 月 14 日

Targeting the Hippo Transducer TAZ in Breast Cancer With Statins

计划入组 78 人 · 首次发布于 2015 年 4 月 15 日

To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)

计划入组 20 人 · 首次发布于 2018 年 8 月 9 日

TAZ antisense oligonucleotides

YAP/TAZ-TEAD inhibitors

ETS-003

JIUYUAN GENE

Triple-Gene LLC

United States

MOMOTARO-GENE INC.

Japan

First Oral Drug MA-5 Shows Promise for Rare Barth Syndrome in Preclinical Studies

Niche-Targeted YAP/TAZ Activation Offers New Paradigm for Bone Marrow Regeneration After Myeloablative Therapy

IAG933, a Novel YAP/TAZ-TEAD Inhibitor, Shows Promise in Preclinical Cancer Models